-income countries in sub-Saharan Africa and Some upper-middle-income countries, as well as countries that have transitioned from lower-middle-income status to upper-middle-income status in the past five years, do not cover the Chinese market
Simcere Pharma and Vivoryon collaborated to target N3pE amyloid protein SIM0408 approved for clinical use
Time of Update: 2022-05-27
SIM0408 is a differentiated oral small molecule investigational drug candidate for Alzheimer's disease with the potential to address multiple key AD pathological mechanisms in a unique mode, including Aβ pathology, neuroinflammation and synaptic damage .
China Resources Pharma's China Pharmaceutical Research Innovative Drug NIP003 Tablets Obtained Clinical Approval
Time of Update: 2022-05-27
Institute, a subsidiary of China Resources Pharma, obtained the "Notice of Drug Clinical Trial Approval" issued by the NMPA, and was approved for clinical use in the prevention of arteriovenous thrombosis. test
Luye Pharma Submits New Drug Application for Lurbinectedin in Hong Kong, China
Time of Update: 2022-05-27
, including all indications for small cell lung cancer . In addition, Luye Pharma has the right to request PharmaMar to transfer the production technology of Lurbinectedin preparations to be produced
Kintor Pharma Announces the First Patient Dosing in the U.S. Phase II Clinical Trial of Furitan for Hair Loss Treatment
Time of Update: 2022-05-27
type of hair loss, androgenetic alopecia accounts for more than 90% of the overall hair loss, and it plagues about 50 million to 60 million men and 30 million to 35 million women in the United States .
Kintor Pharma Announces Completion of Subject Enrollment in China Phase II Clinical Trial of Furitax for the Treatment of Female Hair Loss
Time of Update: 2022-05-27
for female androgenetic alopecia (AGA). The phase II clinical trial in China took just over 4 months to complete the required enrollment of 160 subjects on March 4, 2022 . >
Hansoh Pharma's innovative drug revenue will rise by 169% in 2021, deploying ADC and siRNA
Time of Update: 2022-05-26
Clinical application of innovative drug projects of Hansoh Pharma in the past 5 years*Only the first declaration is countedFrom: Insight database project progress module (http://db.
Fosun Pharma, whose R&D investment ranks among the top 3 in China, is attacking everywhere
Time of Update: 2022-05-26
So far, Fosun Pharma has completed the final piece of the jigsaw puzzle in the prevention and treatment of the new crown, becoming the first and only domestic pharmaceutical company with vaccines, oral drugs and antigen detection products .
Simcere Pharma Appoints Danny Chen as Group Senior Vice President
Time of Update: 2022-05-26
licensing evaluation, and facilitating collaborations . >Danny Chen received his Ph. D. in Pharmacy from The Ohio State University, USA, and obtained academic
【AACR 2022】A total of six preclinical progress of Ascentage Pharma at the 2022 American Association for Cancer Research Annual Meeting
Time of Update: 2022-05-21
>Development of covalent KRAS G12C inhibitor APG-1842 for the treatment of solid tumors> 2664>
Hansoh Pharma Announces Clinical Data of PI3Kα Inhibitor
Time of Update: 2022-05-21
Recently, at the 113th American Association for Cancer Research (AACR) annual meeting in 2022, Hansoh Pharma announced the research data of the single-agent phase I ramp-up trial of its self
The new anti-tumor drug introduced by Lee's Big Pharma has been approved for marketing
Time of Update: 2022-05-18
From https:// Good News Group's anti-tumor drug for the treatment of advanced Hodgkin's lymphoma - Natulan® has been accepted by the NMPA, and the application for priority review will be submitted in May.
Lingke Pharma LNK01004 was approved for clinical use in the treatment of psoriasis in China
Time of Update: 2022-05-17
LNK01004 showed good efficacy and safety in animal experiments .
【2022 ASCO】Ascentage Pharma selected for seven clinical progresses, and multiple pipelines go hand in hand
Time of Update: 2022-05-15
>. Zhai Yifan, Chief Medical Officer of Ascentage Pharma, said: "This will be the fifth consecutive year Ascentage Pharma has appeared at ASCO, and I am delighted to showcase our multiple clinical progress, which further
Hengrui Pharma Appoints New General Manager to Enhance Enterprise Transformation Momentum
Time of Update: 2022-05-13
in a critical period of transformation, and the adjustment of executive personnel for many times is obviously a necessary measure to stimulate the vitality of the organization, strengthen operation management, and increase the momentum of enterprise
Ono Pharma's VelexbruBTK inhibitor approved in Taiwan for the treatment of adult patients with PCNSL
Time of Update: 2022-05-02
Ono Pharmaceutical recently announced that the company's BTK inhibitor Velexbru (tirabrutinib hydrochloride, 80mg tablet
Huadong Medicine's wholly-owned subsidiary signed an equity investment agreement with Heidelberg Pharma
Time of Update: 2022-05-02
On February 28, Huadong Medicine announced that its wholly-owned subsidiary signed an equity investment agreement
TOP5 neuroleptic drug Lonno Pharma risperidone oral solution is about to be approved
Time of Update: 2022-05-02
